Diabetes management for nephrology — new technology and new drugs
The ASN program on diabetes management nephrology 2025 diabetes management for nephrology brings together the nephrology care team to address rapidly advancing diabetes technologies and treatments. Faculty cover continuous glucose monitoring, insulin pumps, automated insulin delivery, and new drug classes that reduce CKD-related complications and progression to kidney failure.
-
1program
-
2025year
Inside this resource
Diabetes technology and CGM
Sessions cover continuous glucose monitoring, insulin pumps, and closed-loop automated insulin delivery systems. Faculty address CGM interpretation, device selection, and how nephrology care teams can implement these technologies for patients with advanced CKD and kidney transplants.
New drug classes for diabetes in CKD
Faculty review new drug classes available to treat diabetes and reduce kidney-related complications, including progression to kidney failure and cardiovascular disease. Sessions address prescribing considerations for patients across all stages of CKD.
Diabetes classification and assessment
The program covers diabetes diagnosis, classification, and assessment with emphasis on correct classification in adults and pediatric populations. Faculty address atypical forms of diabetes and how treatment strategies differ by etiology.
Who this serves
- Nephrologists — implementing diabetes technology and new drugs for CKD patients
- Nephrology care teams — comprehensive diabetes management across advanced CKD and transplant
The chart
| Format | Early Program · Live Course |
|---|---|
| Supported by | Abbott Diabetes Care, Dexcom |
| Publisher | American Society of Nephrology |
| Department | Nephrology |
| Delivery | Instant download after checkout · lifetime re-access |
Verified original fileInstant downloadEncrypted checkout



Jennifer L. –
Well-organized program with clear clinical takeaways. The Abbott and Dexcom support added practical device knowledge.
Robert H. –
Wished for more on transplant-specific diabetes management. The CKD content was thorough though.
Priya N. –
The voluntary CGM activity was unique and eye-opening. Changed how I counsel patients about wearing devices.
Michael R. –
Good overview of new drug classes for diabetes in CKD. The classification session was particularly valuable.
Sarah K. –
The CGM technology sessions were outstanding. Now I feel confident discussing these devices with my CKD patients.